Ads
related to: editas stock
Search results
Is Editas Medicine Stock a Buy Now?
Motley Fool· 11 months agoInvestors tend to move away from somewhat speculative stocks when the economic going gets rough. Editas Medicine's most advanced candidate is EDIT-301,...
Better Gene-Editing Stock: Editas Medicine vs. Bluebird Bio
Motley Fool· 1 year agoEditas Medicine (NASDAQ: EDIT) and Bluebird Bio (NASDAQ: BLUE) are both beaten-down gene-editing...
Are Medical Stocks Lagging Editas Medicine (EDIT) This Year?
Zacks via Yahoo Finance· 1 year agoFor those looking to find strong Medical stocks, it is prudent to search for companies in the group...
Editas Medicine, Inc. (NASDAQ:EDIT) Q4 2023 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 3 months agoEditas Medicine, Inc. (NASDAQ:EDIT) Q4 2023 Earnings Call Transcript February 28, 2024 Editas...
Where Will Editas Medicine Be in 1 Year?
Motley Fool· 2 years agoGene-editing specialist Editas Medicine (NASDAQ: EDIT) fits the bill, which is why the company's shares have plunged this year. Could this be what's in...
Editas Medicine, Inc. (NASDAQ:EDIT) is a favorite amongst institutional investors who own 69%
Simply Wall St. via Yahoo Finance· 6 months agoKey Insights Institutions' substantial holdings in Editas Medicine implies that they have...
Could Editas Medicine Become the Next CRISPR Therapeutics?
Motley Fool via Yahoo Finance· 4 months agoEditas Medicine (NASDAQ: EDIT) and CRISPR Therapeutics (NASDAQ: CRSP) share more than a few...
Editas Medicine, Inc. (NASDAQ:EDIT) is largely controlled by institutional shareholders who own 74%...
Simply Wall St. via Yahoo Finance· 1 year agoEvery investor in Editas Medicine, Inc. (NASDAQ:EDIT) should be aware of the most powerful...
Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics
Motley Fool· 8 months agoIf you've ever thought about investing in the gene-editing biotech space, Editas Medicine (NASDAQ:...
Why Editas Medicine Stock Soared as Much as 42% Higher This Week
Motley Fool via Yahoo Finance· 3 months agoShares of Editas Medicine (NASDAQ: EDIT) charged sharply higher this week, soaring as much as 41.6%,...